國家衛生研究院 NHRI:Item 3990099045/11826
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 914278      在线人数 : 1352
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11826


    题名: The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
    作者: Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J
    贡献者: National Institute of Cancer Research
    摘要: Background: mGPS has been identified as a prognostic factor of OS in patients with pancreatic cancer. Here we report the association between mGPS and OS in a post-hoc analysis of the NAPOLI-1 study (NCT01494506), which demonstrated improved survival for nal-IRI+5-FU/LV vs 5-FU/LV in the treatment of patients with mPDAC previously treated with gemcitabine-based therapy. Methods: All patients treated in the NAPOLI-1 study with available baseline plasma Creactive protein (CRP) and albumin data (data cutoff: Nov 16, 2015) were included in this post-hoc analysis. Eligible patients were stratified by mGPS (mGPS-0: CRP ≤10 mg/L regardless of albumin level; mGPS-1: CRP >10 mg/L, albumin ≥35 g/L; and mGPS-2: CRP >10 mg/L, albumin <35 g/L). OS was assessed in individual and pooled treatment arms. A stepwise Cox regression model of OS was used to evaluate the prognostic significance of mGPS. Results: Baseline plasma C-reactive protein and albumin data was available for N = 184 patients: mGPS-0, n = 79; mGPS-1, n = 88; mGPS-2, n = 17. For patients in pooled treatment arms, median OS was worse for the mGPS-1 group than for the mGPS-0 group (4.0 vs 8.0 months, respectively), but was comparable between the mGPS-2 and mGPS-1 groups (3.2 vs 4.0 months, respectively). Multivariate analysis revealed both mGPS-1 and mGPS-2 were independent predictive factors of death (mGPS-1: HR, 3.34; 95% CI, 2.25–4.95, P < 0.0001; mGPS-2: HR, 5.89; 95% CI, 3.21–10.80, P < 0.001). Similarly, analysis by treatment arm showed OS of patients treated with nal-IRI+5-FU/LV was significantly worse in the mGPS-1 (N = 26) and mGPS-2 (N = 5) groups than in the mGPS-0 (N = 27) group (4.6, 3.3 vs 9.3 months, respectively) Conclusions: Data from this post-hoc analyses of mGPS in patients with mPDAC previously treated with gemcitabine-based are consistent with the reports of the prognostic value of the mGPS in estimating OS. Median OS was significantly improved in pts with a mGPS-0 vs mGPS-1 or mGPS-2, including the treatment group of patients receiving nal-IRI+5-FU/LV
    日期: 2018-10
    關聯: Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
    Link to: https://doi.org/10.1093/annonc/mdy282.132
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000459277301328
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081530416
    显示于类别:[Li-Tzong Chen] Conference Papers/Meeting Abstract

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000459277301328.pdf96KbAdobe PDF243检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈